Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Scientists from the Oxford Parkinson’s Disease Centre (OPDC) and the Edinburgh Prion Unit have developed a new diagnostic test for Parkinson’s disease. The test measures the 'stickiness' of a particular protein in the cerebrospinal fluid.

Positive RT-QuIC signal is only detected in the CSF of patients with pathologically confirmed alpha-synucleinopathy. ThT=thioflavine T; RFU= relative fluorescence unit

This protein, known as alpha-synuclein, forms sticky clumps known as Lewy bodies within the brain cells of patients with Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). There is currently no definitive test that allows doctors to determine if someone has Parkinson's or related disorders, especially at the early stage. So at present the diagnosis is based purely on clinical symptoms and can only be confirmed with a post-mortem examination of the brain. 

These are hugely promising results and we are extending the analysis to a larger cohort of OPDC Discovery samples. We are particularly keen to understand how early these changes can be detected and whether our assay could be used as a predictive test. We also hope to refine our technique to detect alpha-synuclein aggregation in the nasal mucosa collected through a safer and less invasive brushing procedure compared to lumbar puncture required for the CSF collection.

- Laura Parkkinen

Previous efforts to develop a test for alpha-synuclein have produced inconsistent results because the protein is also found in the brain and cerebrospinal fluid (CSF) of healthy subjects. It is only when the protein clumps together that it causes problems. 

An extremely sensitive technology called real-time quaking-induced conversion (RT-QuIC) allows the measurement of stickiness of proteins; this approach has already been used to detect the CSF prion protein in Creutzfeldt-Jakob disease. Dr Laura Parkkinen and her team used this technology in brain material derived from the Oxford Brain Bank and CSF samples from the OPDC Discovery cohort. They were able to detect 'sticky' alpha-synuclein protein in the patients with PD and DLB with sensitivities of 95% and 92%, respectively, and with an overall specificity of 100% when compared to Alzheimer’s and controls.

Interestingly, few patients known to be at risk of developing PD/DLB (i.e. patients with REM sleep behaviour disorder) had a positive result. This suggests that this test could potentially detect patients before their motor and/or cognitive symptoms appear and thus allow the initiation of early treatment that could slow or even stop the disease.

Similar stories

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Royal Academy of Engineering Research Fellowship

Dr Rezvan Farahibozorg has received one of 17 Royal Academy of Engineering Research Fellowships for 2022.

Three New Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.